MultiValent Biotherapies

New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug

MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer. This clinical-stage asset was licensed from China-based Coherent Biopharma.

By Frank Vinluan

The Healthcare Payments Industry Faces a Perception Challenge

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships

Automation Didn’t Dehumanize Care. Bad Systems Did.

We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah